Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.1%

2 terminated/withdrawn out of 22 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

32%

7 trials in Phase 3/4

Results Transparency

31%

5 of 16 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 1
8(42.1%)
Phase 3
5(26.3%)
Phase 2
4(21.1%)
Phase 4
2(10.5%)
19Total
Phase 1(8)
Phase 3(5)
Phase 2(4)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT05560282Phase 3Terminated

Fenfluramine for Adult Dravet Patients

Role: collaborator

NCT05064878Phase 3Active Not Recruiting

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

Role: lead

NCT03936777Phase 3Completed

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Role: lead

NCT05232630Phase 4Recruiting

Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes

Role: collaborator

NCT04398667Terminated

European Non-interventional Study on Refractory Epilepsy With Developmental Delay

Role: lead

NCT03780127Unknown

ZX008 Expanded Access Protocol

Role: lead

NCT02655198Phase 2Unknown

Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy

Role: collaborator

NCT00620425Phase 1Completed

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

Role: lead

NCT01081912Phase 3Completed

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

Role: lead

NCT02244762Phase 1Completed

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment

Role: lead

NCT02197156Phase 2Completed

A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery

Role: lead

NCT00614029Phase 1Completed

A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

Role: lead

NCT02242734Phase 1Completed

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment

Role: lead

NCT00530517Phase 2Completed

A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack

Role: lead

NCT02117141Phase 1Completed

To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules

Role: lead

NCT02126917Phase 1Completed

A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)

Role: lead

NCT01592110Phase 1Completed

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

Role: lead

NCT00619554Completed

A Study on the Intraject Instructions for Use

Role: lead

NCT02222740Phase 2Completed

A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain

Role: lead

NCT01115569Phase 3Completed

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Role: lead